|
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
RECRUITINGPhase 3Sponsored by Hoffmann-La Roche
Actively Recruiting
PhasePhase 3
SponsorHoffmann-La Roche
Started2026-09-30
Est. completion2028-10-20
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →
NCT07843485
Summary
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Participants with BMI ≥ 27 kg/m² * T2D diagnosis as per World Health Organization (WHO) classification (or other locally applicable standards) with HbA1c ≥ 6.5% to ≤ 10% (48-86 mmol/mol), measured by the central laboratory at screening * Stable treatment with either diet and exercise alone, basal insulin, or selected oral glucose-lowering agents, for at least 90 days prior to and during screening * History of at least one self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * History or presence of proliferative diabetic retinopathy, or diabetic macular edema * Current or previous treatment with petrelintide or any other amylin analog
Conditions3
DiabetesObesity or OverweightType 2 Diabetes
Locations2 sites
California
1 siteInstitute for Metabolic Research Los Angeles
Virginia
1 siteManassas Clinical Research Center
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorHoffmann-La Roche
Started2026-09-30
Est. completion2028-10-20
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →
NCT07843485